This inventor holds 2 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignees: The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center, Yeda Research and Develpment & Co. Ltd. Active years: 2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 60 
2 out of 1,168 Years Active: 2024
Title: Moran Rawet Slobodkin: Innovator in Cancer Treatment
Introduction
Moran Rawet Slobodkin is a prominent inventor based in Tel Aviv, Israel. He has made significant contributions to the field of cancer treatment through his innovative work on T-cells. With a total of 2 patents, Slobodkin is recognized for his advancements in chimeric antigen receptor (CAR) technology.
Latest Patents
Slobodkin's latest patents include groundbreaking inventions that enhance the efficacy of T-cells in targeting cancer cells. One of his notable patents involves T-cells modified to express at least two chimeric antigen receptors. This invention allows one CAR to bind specifically to antigens such as CD138, HER2, and CD24, while another CAR targets a different antigen from the same group. This dual-targeting approach is particularly promising for the treatment of ovarian cancer.
Another significant patent focuses on T-cells expressing anti-CD38 and anti-CD138 chimeric antigen receptors. This invention provides T-cells that express two different CARs, enhancing their ability to combat multiple myeloma. The pharmaceutical compositions derived from these dual CAR T-cells offer new avenues for cancer treatment, showcasing Slobodkin's innovative contributions to medical science.
Career Highlights
Throughout his career, Slobodkin has worked with esteemed organizations such as Yeda Research and Development Company and the Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center. His work in these institutions has allowed him to collaborate with leading experts in the field, furthering his research and development efforts.
Collaborations
Some of Slobodkin's notable collaborators include Zelig Eshhar and Tova Waks. Their combined expertise has contributed to the advancement of CAR T-cell therapies, enhancing the potential for innovative cancer treatments.
Conclusion
Moran Rawet Slobodkin's work in the field of cancer treatment through T-cell innovations exemplifies the impact of dedicated research and collaboration. His patents represent significant strides in the fight against cancer, particularly in targeting specific antigens for more effective therapies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile